Long-Term Efficacy and Tolerability of Clozapine Combined with Ziprasidone or Risperidone

Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, University of Heidelberg, Mannheim, Germany.
Pharmacopsychiatry (Impact Factor: 2.17). 08/2010; 43(6):216-20. DOI: 10.1055/s-0030-1254089
Source: PubMed

ABSTRACT Treatment resistance in schizophrenia often leads to add-on of atypical antipsychotics to clozapine.
In a randomized trial, we recently obtained evidence for comparable efficacy and differential side effects of clozapine in combination with ziprasidone (CZ, N=12) versus risperidone (CR, N=12). Here, we present the open-label, long-term evaluations of these patients after 26 and 52 weeks.
Sustained improvements of psychopathology as assessed by PANSS (positive and negative syndrome scale), SANS (scale for the assessment of negative symptoms), and HAMD (Hamilton depression scale) were documented in both subsamples being treated according to protocol, while dropouts reduced the study sample after 26 (CZ: reduced by -4; CR: -2) and 52 weeks (CZ: -0; CR: -5). We observed a slight increase of akathisia in the CZ group whereas general clozapine-associated side effects improved.
The combinations of clozapine with ziprasidone or risperidone exhibit long-term efficacy, but the level of evidence is limited. Further head-to-head comparisons of atypical antipsychotics as add-on to clozapine are necessary.

Download full-text


Available from: Mathias Zink, Nov 14, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: A method to estimate the shape of the foundation piles is described. The head of the pile is hit with a small hammer and the reflected wave is recorded with a vibration pick-up attached to the same head. The method automatically estimates the shape of the pile from the recorded wave. By computer simulations and experiments using model piles, it is confirmed that the proposed method correctly estimates the shape of the underground piles
    Acoustics, Speech, and Signal Processing, 1988. ICASSP-88., 1988 International Conference on 01/1991; DOI:10.1109/ICASSP.1991.151077
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper describes the design and development of a Java-based distributed system tool-environment for image analysis with special attention given to synthetic aperture radar (SAR) imaging applications. This tool-environment allows a given user to effect important image processing functions such as to visualize, manipulate, improve, filter, detect edges, reduce the noise, as well as to carry out raw data formatting, image formation operations, Kronecker array filtering, and feature extraction on SAR images. Also, this system has the unique option of allowing end-users to add their own customized algorithms as encapsulated operators to act on elements resident on local or remote SAR images-servers on a computer network.
    Image and Signal Processing and Analysis, 2003. ISPA 2003. Proceedings of the 3rd International Symposium on; 10/2003
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review addresses practical clinical issues related to the use of ziprasidone in the treatment of schizophrenia using information from clinical trials, unpublished data, manufacturer's information, and input from an expert faculty of European psychiatrists with extensive experience of the use of ziprasidone, both in clinical trials and in everyday clinical practice. A Medline search of published data (1998 - 2010) was carried out, together with a review of unpublished data and manufacturer's information. In addition, expert opinion was sought from psychiatrists with extensive experience of ziprasidone in the treatment of schizophrenia in clinical settings across Europe. This review has been undertaken to determine how the information from clinical trials can be optimally translated into 'real-life' practice and to establish how a decade of experience with ziprasidone in clinical practice can inform its optimal use to maximize effectiveness and minimize side effects. Effective use of ziprasidone in everyday clinical practice usually requires rapid titration to doses in the range of 120 - 160 mg/day and administration with proper meals, thereby achieving the high levels of schizophrenia symptom control reported in clinical trials. Additional guidance is provided about effective management of side effects, and appropriate coadministration of benzodiazepines and other agents, to achieve desired outcomes.
    Expert Opinion on Pharmacotherapy 09/2010; 11(13):2199-220. DOI:10.1517/14656566.2010.507630